Inclusion Criteria:

- Over or equal to 18 years of age.

- ECOG performance status less than or equal to 1

- Adequate organ function.

- History of radical prostatectomy with histopathologic documentation of adenocarcinoma
of the prostate.

- PSA over or equal to 0.2 ng/ml or less than or equal to 0.4 ng/ml. This includes
patients whose PSA never becomes detectable. PSA progression must be measured by two
consecutive samples, each separated by over or equal to 7 days. The PSA values of the
two consecutive sample values must be greater than the previous (baseline) value, not
greater than each other.

Exclusion Criteria:

- Known sites of measurable prostate cancer or bone scan positive for metastatic
prostate cancer. (patients with a positive Prostascint scan will not be excluded)

- Prior therapy for prostate cancer except RP and neoadjuvant hormonal therapy. This
includes chemo, hormonal (except neoadjuvant), RT, and biologic therapy.

- Lack of physical integrity of the upper GI tract, malabsorption syndromes, or
inability to tolerate or absorb oral medications, including Crohn's disease and
ulcerative colitis.

- Other concurrent immunotherapy, RT, chemotherapy,or ancillary therapy considered
investigational (utilized for non-FDA approved indications and the context of a
research investigation)and any chemotherapy not included in the study protocol.